Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Merck Sharp & Dohme Corp.

Burst CME: Investigating the Impact of Emerging Agents in Heart Failure

Release Date: March 31, 2021
Expiration Date: March 31, 2022

Activity Overview

Heart failure is a serious, debilitating disease that undermines patients’ functional abilities and quality of life. It is vital to ensure that all patients with heart failure are treated with appropriate guideline-directed medical therapy. This activity gives an overview of the mechanisms of action and key outcomes of novel and emerging treatment strategies in heart failure. Throughout, Stephen Greene, MD, provides answers to important questions on this subject.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Merck Sharp & Dohme Corp.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward cardiologists, specialty nurse practitioners and physician assistants, and primary care physicians engaged in the care of patients with heart failure (HF).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the mechanisms of action for newer and emerging agents being evaluated for the treatment of HF
  • Analyze recent efficacy and safety data for newer and emerging agents being evaluated for the treatment of HF

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Stephen J. Greene, MD
Stephen J. Greene, MD
Assistant Professor, Division of Cardiology
Duke Clinical Research Institute and Duke University School of Medicine
Durham, NC

Disclosures: Grant/Research Support: Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer. Consultant: Amgen, AstraZeneca.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By